Recent

% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

  • wolfmanran wolfmanran May 15, 2013 10:59 AM Flag

    CLINCAL DATA #3

    "These data are quite remarkable," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "In previous clinical studies, a decline in the HIV reservoir has never been observed in subjects on long-term anti-retroviral therapy (ART) and any increase in the levels of CD4 cells in HIV-infected subjects is often associated with a concomitant increase in the size of the reservoir. In contrast, a single SB-728-T treatment of subjects on long-term ART produced a significant and durable improvement in CD4 count and, in the majority of subjects, a notable decrease in the HIV reservoir over time. An observed correlation with circulating ZFN CCR5 protected CD4 cells is extremely promising

 
SGMO
9.97-0.19(-1.87%)Jul 2 4:00 PMEDT